These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 11326092)

  • 1. Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax.
    Sellman BR; Mourez M; Collier RJ
    Science; 2001 Apr; 292(5517):695-7. PubMed ID: 11326092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A soluble receptor decoy protects rats against anthrax lethal toxin challenge.
    Scobie HM; Thomas D; Marlett JM; Destito G; Wigelsworth DJ; Collier RJ; Young JA; Manchester M
    J Infect Dis; 2005 Sep; 192(6):1047-51. PubMed ID: 16107958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing a polyvalent inhibitor of anthrax toxin.
    Mourez M; Kane RS; Mogridge J; Metallo S; Deschatelets P; Sellman BR; Whitesides GM; Collier RJ
    Nat Biotechnol; 2001 Oct; 19(10):958-61. PubMed ID: 11581662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiology. Fighting anthrax with a mutant toxin.
    Olsnes S; Wesche J
    Science; 2001 Apr; 292(5517):647-8. PubMed ID: 11330322
    [No Abstract]   [Full Text] [Related]  

  • 5. A dominant-negative therapy for anthrax.
    Leppla SH
    Nat Med; 2001 Jun; 7(6):659-60. PubMed ID: 11385497
    [No Abstract]   [Full Text] [Related]  

  • 6. Functional characterization of peptide-based anthrax toxin inhibitors.
    Gujraty K; Sadacharan S; Frost M; Poon V; Kane RS; Mogridge J
    Mol Pharm; 2005; 2(5):367-72. PubMed ID: 16196489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of new dominant-negative mutants of anthrax protective antigen using directed evolution.
    Wu G; Feng C; Cao S; Guo A; Liu Z
    Appl Biochem Biotechnol; 2012 Nov; 168(5):1302-10. PubMed ID: 22948605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydrophobic residues Phe552, Phe554, Ile562, Leu566, and Ile574 are required for oligomerization of anthrax protective antigen.
    Ahuja N; Kumar P; Bhatnagar R
    Biochem Biophys Res Commun; 2001 Sep; 287(2):542-9. PubMed ID: 11554763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions between anthrax toxin receptors and protective antigen.
    Scobie HM; Young JA
    Curr Opin Microbiol; 2005 Feb; 8(1):106-12. PubMed ID: 15694864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthrax toxin rafts into cells.
    Kurzchalia T
    J Cell Biol; 2003 Feb; 160(3):295-6. PubMed ID: 12566425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dominant negative mutant of Bacillus anthracis protective antigen inhibits anthrax toxin action in vivo.
    Singh Y; Khanna H; Chopra AP; Mehra V
    J Biol Chem; 2001 Jun; 276(25):22090-4. PubMed ID: 11278644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The LDL receptor-related protein LRP6 mediates internalization and lethality of anthrax toxin.
    Wei W; Lu Q; Chaudry GJ; Leppla SH; Cohen SN
    Cell; 2006 Mar; 124(6):1141-54. PubMed ID: 16564009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Where and how do anthrax toxins exit endosomes to intoxicate host cells?
    Puhar A; Montecucco C
    Trends Microbiol; 2007 Nov; 15(11):477-82. PubMed ID: 17983750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthrax protective antigen: efficiency of translocation is independent of the number of ligands bound to the prepore.
    Zhang S; Cunningham K; Collier RJ
    Biochemistry; 2004 May; 43(20):6339-43. PubMed ID: 15147218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion protein of Delta 27LFn and EFn has the potential as a novel anthrax toxin inhibitor.
    Kong Y; Guo Q; Yu C; Dong D; Zhao J; Cai C; Hou L; Song X; Fu L; Xu J; Chen W
    FEBS Lett; 2009 Apr; 583(8):1257-60. PubMed ID: 19332063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the cellular receptor for anthrax toxin.
    Bradley KA; Mogridge J; Mourez M; Collier RJ; Young JA
    Nature; 2001 Nov; 414(6860):225-9. PubMed ID: 11700562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dynamin inactivation on pathways of anthrax toxin uptake.
    Boll W; Ehrlich M; Collier RJ; Kirchhausen T
    Eur J Cell Biol; 2004 Jul; 83(6):281-8. PubMed ID: 15511085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis.
    Mourez M; Yan M; Lacy DB; Dillon L; Bentsen L; Marpoe A; Maurin C; Hotze E; Wigelsworth D; Pimental RA; Ballard JD; Collier RJ; Tweten RK
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):13803-8. PubMed ID: 14623961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin.
    Mogridge J; Mourez M; Collier RJ
    J Bacteriol; 2001 Mar; 183(6):2111-6. PubMed ID: 11222612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deletion mutants of protective antigen that inhibit anthrax toxin both in vitro and in vivo.
    Ahuja N; Kumar P; Alam S; Gupta M; Bhatnagar R
    Biochem Biophys Res Commun; 2003 Aug; 307(3):446-50. PubMed ID: 12893241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.